113 - Vaxxinity Takes on Neurodegenerative Diseases with Vaccines - Potential Short Opportunity?
Video Sponsor - http://workinbiotech.com/ In this episode, I go through a company called Vaxxinity, who are trying to develop vaccines for t...
Radio and PodcastLive Radio & PodcastsScience & Medicine
Breaking Biotech
Matt breaks down relevant biotech stocks, analyzing their data and determining if they are a good investment.
Breaking Biotech Podcast Guide
Listen to Breaking Biotech, a Science & Medicine podcast by Matthew Lepoire. Stream 10 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Science & Medicine podcasts.
Episodes
10 episodes are available for this podcast.
Discover More
Explore Science & Medicine podcasts, Italy podcasts and English podcasts.
Episodes
10 episodes112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRA
In this episode, I take a look at 6 different biotechs and talk about recent updates in each one. Here is the breakdown: BTAI - 1:00 TGTX -...
111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich
Achieve Life Sciences is developing Cytisinicline for the treatment of smoking cessation. The drug has been available in Eastern Europe for...
110 - Kodiac Sciences FALLS on Negative Wet AMD Readout! Buying Opportunity or Falling Knife??
Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their recent P3 wet AMD data readout fail...
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results
Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export...
108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD
The NASH space has seen some setbacks in the last couple years, but a few players continue to make nice progress on their clinical trials. M...
107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients | Interview with CEO Sujal Shah
CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis (PBC). PBC currently affects around 130K pati...
106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!
CRISPR is an exciting space, with a number of companies finally sharing early clinical data in 2021. NTLA benefitted the most from this by d...
105 - Neurodegenerative Disease Recap! ALXO and LGVN updates plus Breaking Breaking 2021 Top Trades
ALXO announces new HR-MDS data that disappoints! I talk about the comparison to Magrolimab data and why I think ALXO is still a buy. LGVN pu...
104 - Biotech Bear Market Offers SIGNIFICANT Opportunity in Oncology - CRIS! Longeveron Rises on ODD
Curis is an oncology company trying to develop an inhibitor of IRAK-4. They have shown positive results in AML/MDS in spliceosome/FLT3 mutat...